Agudo‐Fernández S, Milla CC, Blanco AG, et al. - Researchers performed a retrospective cohort study to assess the risk of gastrointestinal bleeding in anticoagulated patients and compare the classic treatment with new anticoagulants. Between 2012 and 2016, they determined the risk of gastrointestinal bleeding in patients treated with acenocoumarol/dabigatran/rivaroxaban. One thousand two hundred thirteen patients were chosen, 52.7% males, mean age of 72.6 years old. There were no differences in the risk of gastrointestinal bleeding between the anticoagulants studied. Previous gastrointestinal bleeding was regarded as an independent risk factor. The HAS‐BLED score should be considered when making clinical decisions about whether or not to prescribe anticoagulant treatment.